Loading …

Idera Pharmaceuticals merged with Aceragen, Inc, a rare disease biopharmaceutical company, in September 2022. Aceragen subsequently began its wind-down in mid-2023.
Annual Revenue$1M to $5M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more